ZA200108619B - Adjuvant composition comprising saponin and an immunostimulatory oligonucleotide. - Google Patents
Adjuvant composition comprising saponin and an immunostimulatory oligonucleotide.Info
- Publication number
- ZA200108619B ZA200108619B ZA200108619A ZA200108619A ZA200108619B ZA 200108619 B ZA200108619 B ZA 200108619B ZA 200108619 A ZA200108619 A ZA 200108619A ZA 200108619 A ZA200108619 A ZA 200108619A ZA 200108619 B ZA200108619 B ZA 200108619B
- Authority
- ZA
- South Africa
- Prior art keywords
- saponin
- adjuvant composition
- immunostimulatory oligonucleotide
- immunostimulatory
- oligonucleotide
- Prior art date
Links
- 108091034117 Oligonucleotide Proteins 0.000 title 1
- 239000002671 adjuvant Substances 0.000 title 1
- 230000003308 immunostimulating effect Effects 0.000 title 1
- 239000001397 quillaja saponaria molina bark Substances 0.000 title 1
- 229930182490 saponin Natural products 0.000 title 1
- 150000007949 saponins Chemical class 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/002—Protozoa antigens
- A61K39/015—Hemosporidia antigens, e.g. Plasmodium antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Oncology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Communicable Diseases (AREA)
- Neurology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Virology (AREA)
- Cardiology (AREA)
- Pulmonology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB9908885.8A GB9908885D0 (en) | 1999-04-19 | 1999-04-19 | Vccine |
Publications (1)
Publication Number | Publication Date |
---|---|
ZA200108619B true ZA200108619B (en) | 2002-11-27 |
Family
ID=10851789
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ZA200108619A ZA200108619B (en) | 1999-04-19 | 2001-10-19 | Adjuvant composition comprising saponin and an immunostimulatory oligonucleotide. |
Country Status (13)
Country | Link |
---|---|
EP (2) | EP1905449A3 (xx) |
JP (1) | JP5307859B2 (xx) |
KR (1) | KR20020067617A (xx) |
CN (2) | CN1911443A (xx) |
AR (1) | AR023536A1 (xx) |
CO (1) | CO5241279A1 (xx) |
GB (1) | GB9908885D0 (xx) |
IL (2) | IL145982A (xx) |
MY (1) | MY127452A (xx) |
NO (1) | NO20110994L (xx) |
PL (2) | PL203894B1 (xx) |
SI (1) | SI1187629T1 (xx) |
ZA (1) | ZA200108619B (xx) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2013522287A (ja) * | 2010-03-18 | 2013-06-13 | ノバルティス アーゲー | 血清群b髄膜炎菌のためのアジュバント添加ワクチン |
US20130259948A1 (en) | 2010-09-21 | 2013-10-03 | National Institute Of Immunology | Spray dried powder formulation for vaccines entrapping alum and the antigen in biodegradable polymer particles |
EP3078381A1 (en) * | 2015-04-10 | 2016-10-12 | Warszawski Uniwersytet Medyczny | Horse chestnut extract or escins for the treatment of alzheimer's disease |
WO2019118393A1 (en) * | 2017-12-11 | 2019-06-20 | Board Of Regents, The University Of Texas System | Dry adjuvanted immune stimulating compositions and use thereof for mucosal administration |
CN114767844A (zh) * | 2022-04-28 | 2022-07-22 | 泰州拜奥生物技术有限公司 | 一种水痘-带状疱疹病毒疫苗及其应用 |
CN116159134A (zh) * | 2023-01-31 | 2023-05-26 | 四川大学 | 七叶皂苷和/或其盐化合物作为佐剂在疫苗中的应用 |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4806350A (en) * | 1986-04-18 | 1989-02-21 | Norden Laboratories, Inc. | Vaccine formulation |
GB9326253D0 (en) * | 1993-12-23 | 1994-02-23 | Smithkline Beecham Biolog | Vaccines |
US6207646B1 (en) * | 1994-07-15 | 2001-03-27 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
UA56132C2 (uk) * | 1995-04-25 | 2003-05-15 | Смітклайн Бічем Байолоджікалс С.А. | Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини |
GB9513261D0 (en) * | 1995-06-29 | 1995-09-06 | Smithkline Beecham Biolog | Vaccines |
EP0855184A1 (en) * | 1997-01-23 | 1998-07-29 | Grayson B. Dr. Lipford | Pharmaceutical composition comprising a polynucleotide and an antigen especially for vaccination |
CA2281838A1 (en) * | 1997-02-28 | 1998-09-03 | University Of Iowa Research Foundation | Use of nucleic acids containing unmethylated cpg dinucleotide in the treatment of lps-associated disorders |
EP0988053A1 (en) * | 1997-06-11 | 2000-03-29 | Aquila Biopharmaceuticals, Inc. | Purified saponins as oral adjuvants |
GB9718901D0 (en) * | 1997-09-05 | 1997-11-12 | Smithkline Beecham Biolog | Vaccine |
DK1659179T3 (da) * | 1998-02-05 | 2011-10-10 | Glaxosmithkline Biolog Sa | Tumor-associerede antigenderivater fra MAGE-familien og nucleinsyresekvenser kodende for dem anvendt til fremstilling af fusionsproteiner og sammensætninger til vaccination |
SI1077722T1 (sl) * | 1998-05-22 | 2007-02-28 | Ottawa Health Research Inst | Metode in produkti za induciranje sluznicne imunosti |
AU773204C (en) * | 1998-08-10 | 2005-05-19 | Antigenics Llc | Compositions of CPG and saponin adjuvants and methods thereof |
GB9915204D0 (en) * | 1999-06-29 | 1999-09-01 | Smithkline Beecham Biolog | Vaccine |
JP2003527352A (ja) * | 2000-01-13 | 2003-09-16 | アンティジェニクス インコーポレーテッド | Cpgおよびサポニンの自然免疫刺激化合物、ならびにそれらの方法 |
CA2396871A1 (en) * | 2000-01-20 | 2001-12-20 | Ottawa Health Research Institute | Immunostimulatory nucleic acids for inducing a th2 immune response |
-
1999
- 1999-04-19 GB GBGB9908885.8A patent/GB9908885D0/en not_active Ceased
-
2000
- 2000-04-04 CN CNA200610100225XA patent/CN1911443A/zh active Pending
- 2000-04-04 CN CNB2005101096981A patent/CN100542606C/zh not_active Expired - Lifetime
- 2000-04-04 KR KR1020017013357A patent/KR20020067617A/ko not_active Application Discontinuation
- 2000-04-04 EP EP07121768A patent/EP1905449A3/en not_active Withdrawn
- 2000-04-04 SI SI200030557T patent/SI1187629T1/xx unknown
- 2000-04-04 EP EP20040076239 patent/EP1541170A1/en not_active Withdrawn
- 2000-04-04 PL PL384581A patent/PL203894B1/pl unknown
- 2000-04-04 PL PL384582A patent/PL205547B1/pl unknown
- 2000-04-14 CO CO00027742A patent/CO5241279A1/es not_active Application Discontinuation
- 2000-04-17 MY MYPI20001620A patent/MY127452A/en unknown
- 2000-04-18 AR ARP000101809A patent/AR023536A1/es not_active Application Discontinuation
-
2001
- 2001-10-16 IL IL145982A patent/IL145982A/en not_active IP Right Cessation
- 2001-10-19 ZA ZA200108619A patent/ZA200108619B/xx unknown
-
2008
- 2008-02-25 IL IL189736A patent/IL189736A0/en not_active IP Right Cessation
-
2011
- 2011-07-07 NO NO20110994A patent/NO20110994L/no not_active Application Discontinuation
- 2011-08-02 JP JP2011169244A patent/JP5307859B2/ja not_active Expired - Lifetime
Also Published As
Publication number | Publication date |
---|---|
IL145982A (en) | 2009-12-24 |
JP2011241222A (ja) | 2011-12-01 |
AR023536A1 (es) | 2002-09-04 |
KR20020067617A (ko) | 2002-08-23 |
NO20110994L (no) | 2001-11-22 |
CN1739800A (zh) | 2006-03-01 |
EP1541170A1 (en) | 2005-06-15 |
CN1911443A (zh) | 2007-02-14 |
SI1187629T1 (en) | 2005-04-30 |
GB9908885D0 (en) | 1999-06-16 |
IL189736A0 (en) | 2008-06-05 |
CN100542606C (zh) | 2009-09-23 |
PL205547B1 (pl) | 2010-04-30 |
PL203894B1 (pl) | 2009-11-30 |
JP5307859B2 (ja) | 2013-10-02 |
EP1905449A3 (en) | 2009-03-25 |
CO5241279A1 (es) | 2003-01-31 |
MY127452A (en) | 2006-12-29 |
EP1905449A2 (en) | 2008-04-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HUP0200815A2 (en) | Adjuvant composition comprising saponin and an immunostimulatory oligonucleotide | |
HUP0303720A3 (en) | Adjuvant composition comprising an immunostimulatory oligonucleotide and a tocol | |
GB2371747B (en) | Metal-containing compositions, preparations and uses | |
ZA200201810B (en) | Combined vaccine compositions. | |
EG24742A (en) | Vaccine composition. | |
ZA200004956B (en) | Vaccine composition. | |
MX265024B (es) | Formulaciones de glifosato de potasio. | |
HUP0301229A3 (en) | Immunostimulatory oligodeoxynucleotides | |
HK1047697A1 (en) | Immunostimulatory nucleic acids. | |
ZA200200743B (en) | Preserved pharmaceutical formulations. | |
IL148247A (en) | Vaccine and its uses | |
HK1045462A1 (en) | Combined preparations comprising morpholine anthracyclines and anticancer agent | |
IL151496A0 (en) | Processes for preparing clarithromycin and clarithromycin intermediate, essentially oxime-free clarithromycin, and pharmaceutical composition comprising the same | |
AU7003101A (en) | Qs-21 and il-12 as an adjuvant combination | |
ZA996814B (en) | Aluminosilicate compositions, preparation and use. | |
MXPA02003232A (es) | Composiciones y metodos para alternar la expresion de genes. | |
HUP0201220A2 (en) | Adjuvant combination formulations | |
MXPA02003660A (es) | Composicion herbicida y adyuvante. | |
HK1053132A1 (en) | Silicone gel composition. | |
ZA200108619B (en) | Adjuvant composition comprising saponin and an immunostimulatory oligonucleotide. | |
MXPA03000514A (es) | Lectinas relacionadas a inmunoglobulina con enlace a acido sialico y usos de los mismos. | |
AU2001235616A1 (en) | Immunostimulatory oligonucleotides | |
AU2001261317A1 (en) | Immunostimulant compositions and associated methods | |
MXPA03004071A (es) | Formulaciones de combinacion de adyuvantes. | |
MXPA01010701A (es) | Vacuna. |